



The Open Rheumatology Journal

Supplementary Material

Content list available at: www.benthamopen.com/TORJ/

DOI: 10.2174/1874312901812010179, 2018, 12, k



RESEARCH ARTICLE


Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study

Paul Emery^{1,*}, Ronald Pedersen², Jack Bukowski² and Lisa Marshall²¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and the National Institute for Health Research Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK²Pfizer, Collegeville, PA, USA

Received: June 20, 2018

Revised: August 10, 2018

Accepted: October 1, 2018



*Patients who did not achieve LDA at these time points were given corticosteroid boosts.

[†]Over 2–4 weeks.

DAS28: Disease Activity Score for 28 joint counts; ETN: etanercept; LDA: low disease activity; MTX: methotrexate;

P: phase; PBO: placebo; QW: once weekly; R: randomized; RA: rheumatoid arthritis; Rp: responders; SC: subcutaneous.

Supplemental Fig. (1). Study design and patient disposition.

* Address correspondence to this author at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and the National Institute for Health Research Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Tel: +44 0113 392 4884; E-mail: p.emery@leeds.ac.uk

© 2018 Emery *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<https://creativecommons.org/licenses/by/4.0/legalcode>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.